Human anti-ganglioside (GM1)antibody(IgG)ELISA Kit

The human anti-ganglioside (GM1) antibody (IgG) ELISA kit is specifically designed for detecting IgG antibodies against GM1 ganglioside in human serum samples. The assay principle of this kit is qualitative, allowing for the determination of the presence or absence of anti-GM1 IgG antibodies in the samples. The kit's specifications indicate a relatively short assay time of 1-5 hours, making it efficient for laboratory use. It requires a small sample volume of 50-100 µl of serum and operates at a detection wavelength of 450 nm. These parameters contribute to the kit's user-friendly nature and suitability for high-throughput screening purposes. The widespread use of this kit in multiple studies underscores its reliability and relevance in anti-GM1 IgG-associated research. Gangliosides are known to be highly immunogenic in humans, and the presence of anti-GM1 antibodies has been associated with conditions such as Guillain-Barré syndrome (GBS) and critical illness polyneuromyopathy (CIPNM) [1][2].

References:
[1] M. Odaka, N. Yuki, H. Yoshino, T. Kasama, S. Handa, F. Irieet al., "n‐glycolylneuraminic acid–containing gm1 is a new molecule for serum antibody in guillain‐barré syndrome", Annals of Neurology, vol. 43, no. 6, p. 829-834, 1998. https://doi.org/10.1002/ana.410430619
[2] J. Luo, Z. Xia, Y. Che, & K. Zhou, "Characteristics, treatments, and prognosis of a critical illness polyneuromyopathy patient with positive anti‐gm1 after severe traumatic brain injury: a case report", Clinical and Experimental Pharmacology and Physiology, vol. 48, no. 6, p. 831-836, 2021. https://doi.org/10.1111/1440-1681.13496